


Amendments to the Claims


Claim 1. (Cancelled)

Claim 2 (Currently amended) A compound of Claim 1 of Formula I(a):

I(a)

where:

R^1 is $(C_3-C_7$ cycloalkyl $)_{0-1}(C_1-C_6$ alkyl $), (C_3-C_7$ cycloalkyl $)_{0-1}(C_2-C_6$ alkenyl $), (C_3-C_7$ cycloalkyl $)_{0-1}(C_2-C_6$ alkynyl $)$ or C_3-C_7 cycloalkyl, each optionally substituted with up to three groups independently selected from halo, hydroxy, thiol, cyano, trifluoromethyl, trifluoromethoxy, C_1-C_6 alkoxy, C_3-C_7 cycloalkoxy, oxo, and NR^9R^{10} , hydrogen, biphenyl



substituted with halo;

 X is CH , N , or N^+O^- ; Y is CR^{16} , N , or N^+O^- ; Q is CR^{17} , N , or N^+O^- ; R^2 is C_1-C_7 alkyl, benzyl optionally mono- or difluorinated in the phenyl ring

monosubstituted in the phenyl ring with a substituent selected from the group consisting of halo, C_1-C_6 alkoxy optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, and C_1-C_6 alkylthio optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, or benzyl optionally disubstituted in the phenyl ring with a first substituent independently selected from halo and a second substituent independently selected from halo, C_1-C_6 alkoxy optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl, and C_1-C_6 alkylthio optionally substituted in the alkyl chain with C_3-C_7 cycloalkyl;

R^6 is fluoro, hydroxy, p-toluenesulfonyloxy, R^{34} , $-CH_2C(O)R^{35}$, or $-OC(O)NR^{36}$; or R^5 and R^6 taken together form $=CHC(O)(C_1-C_4$ alkoxy $)$;

R^9 is hydrogen, C_1 - C_6 alkyl, or phenyl;

R^{10} is hydrogen, C_1 - C_6 alkyl, phenyl, $C(O)(C_1$ - C_6 alkyl), or $SO_2(C_1$ - C_6 alkyl);

R^{11} and R^{12} are independently selected from the group consisting of methyl, ethyl, and propyl;

R^{13} is hydrogen or C_1 - C_6 alkyl;

R^{14} is C_1 - C_6 cycloalkyl, C_1 - C_6 alkyl, or CH_2R^{15} ;

R^{15} is CF_2R^{16} , OR^{20} , $CH_2C(O)CH_3$, $S(O)_{2-}R^{21}$, $NR^{22}SO_2R^{23}$, (C_1 - C_6 alkoxy)-carbonyl, phenyl optionally substituted with halo, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,1-dioxo-2,3,4,5-tetrahydroisothiazol-2-yl, or tetrazol-5-yl optionally substituted with C_1 - C_2 alkyl;

R^{16} is hydrogen, chloro, isobutyl, CH_2R^{24} , CF_2R^{25} , 1,1,1-trifluoro-2-hydroxyethyl-2-yl, C_2 - C_6 alkenyl optionally substituted with one or two fluorine atoms, OR^{26} , $C(O)R^{27}$, $N(methyl)(methylsulfonyl)$, $N(methyl)(acetyl)$, pyrrolidin-2-on-1-yl, methylsulfonyl, N,N -dimethylaminosulfonyl, phenyl optionally substituted with one or two substituents selected from the group consisting of hydroxymethyl, methoxy, fluoro, and methylsulfonyl, 1,3-dioxolan-2-yl, 1,3-dithiolan-2-yl, 1,3-oxathiolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithian-2-yl, pyridinyl, thiazolyl, oxazolyl, or 1,2,4-oxadiazolyl optionally substituted with methyl;

R^{17} is hydrogen or fluoro;

R^{18} is ethynyl or cyclopropyl;

R^{19} is hydrogen or methyl;

R^{20} is difluoromethyl or methanesulfonyl;

R^{21} is C_1 - C_6 alkyl, C_1 - C_6 cycloalkyl, phenyl, or $NR^{20}R^{21}$;

R^{22} is hydrogen, C_1 - C_6 alkyl optionally substituted with up to 3 fluorine atoms, or C_1 - C_6 cycloalkyl;

R^{23} is C_1 - C_6 alkyl or C_1 - C_6 cycloalkyl;

R^{24} is fluoro, hydroxy, or C_1 - C_6 alkoxy;

R^{25} is hydrogen, phenyl, or furyl;

R^{26} is C_1 - C_6 alkyl optionally substituted with one or two fluorine atoms;

R^{27} is C_1 - C_6 alkyl, C_1 - C_6 cycloalkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkoxy, $NR^{28}R^{29}$, pyrrolidin-1-yl optionally substituted with methyl or one or two fluorine atoms, piperidin-1-yl, phenyl, pyridinyl, or furyl;

R^{28} is hydrogen or methyl;

R^{29} is methyl, ethyl, or propyl;

R^{30} is hydrogen or methyl;

R^{34} is methyl; or

R^{29} and R^{34} taken together with the nitrogen atom to which they are attached form a pyrrolidine or piperidine ring;

R^{32} is C_1-C_{10} alkyl optionally substituted with 1-6 fluorine atoms, oxo, or one or two hydroxy groups, C_2-C_6 alkenyl, or $-(CH_2)_{0-3}R^{33}$;

R^{33} is C_3-C_7 cycloalkyl or phenyl each optionally substituted with one or two substitutents independently selected from the group consisting of halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, trifluoromethyl, and trifluoromethoxy, or R^{33} is adamantyl;

R^{34} is hydrogen, R^{32} , or $-(CH_2)_{0-2}OR^{32}$;

R^{35} is hydroxy, C_1-C_6 alkoxy, or $NR^{37}R^{38}$ where R^{37} and R^{38} are independently hydrogen or C_1-C_6 alkyl, or R^{37} and R^{38} , taken together with the nitrogen to which they are attached, form a piperidine ring optionally substituted with C_1-C_6 alkyl, a homopiperidine ring, a morpholine ring, or a pyrrolidine ring optionally substituted with $(C_1-C_6$ alkoxy)methyl;

R^{36} is C_4-C_6 alkyl or adamantyl;

or a pharmaceutically acceptable salt thereof; provided that: a) no more than one of X, Y, and Q may be N or N^+-O^- ; and b) when X is CH, Y is CR^{16} , and Q is CR^{17} , then one of R^{16} and R^{17} is other than hydrogen.

Claims 3-7 (Cancelled)

Claim 8 (Currently amended): A pharmaceutical formulation composition comprising a compound of Claim 2, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

Claims 9-10 (Cancelled)

Claim 11 (Currently amended) A method for the inhibition of production of A- β peptide comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 2.

Claim 12 (Cancelled)

Claim 13 (New) A compound of Claim 2 where R^2 is benzyl.